TOR-1 Activity Description

Activity Title TOR-1

Activity ID: 38272
Activity Title: To assist WHO with measurement of mortality from hepatitis and other causes of chronic liver diseases. Also to document the impact of COVID-19 pandemic on the implementation of same
Link to TOR: TOR1
Name(s) of responsible staff at the institution: Dr. S K Sarin, Dr. Manoj Sharma, Dr. Ashok Choudhury, Dr. Ankur Jindal, Dr. Manya Prasad.
Type of activity: Collection and collation of information

Why WHO is asking for this activity and how WHO will use the deliverables? : It is important to understand the causes of chronic liver disease and cirrhosis including those due to non-infective pathology. Understanding the contribution of viral hepatitis B and C in development of cirrhosis has both preventive and therapeutic implications.

COVID-19 has impacted the implementation of Hepatitis control programs and accessibility for therapeutic regimens. This activity will contribute in informing WHO’s work in this regard and on identifying measures to scale up the efforts on the subject matter. WHO may also use the outcomes of this activity to inform its work towards identifying liver health approaches integrated to universal health coverage (UHC)”

What concrete actions will be taken by the designated institution? Be specific. : Under WHO’s leadership, the proposed collaborating centre will:-
analyze the data obtained from various leading institutes through WHO Regional office to apply the attributable fraction of cirrhosis and HCC to the national mortality data. It will collect. analyze and interpret the data as to evaluate the impact of hepatitis testing and treatment on mortality. It will also collect the information on impact of COVID-19 pandemic on the liver health.

What will be WHO’s role in this activity? : WHO will lead the activity and liaise with the proposed collaborating centre and support them in getting the data from different available sources in the member states Expected deliverables: An analytic report will be prepared about information on relative contribution of alcohol, HBV, HCV, Non-Alcoholic Fatty Liver Diseases (NAFLD), autoimmune and other causes to the occurrence of chronic liver diseases (cirrhosis and hepatocellular carcinoma {HCC]) Another report on impact of COVID-19 on liver health, follow up and management of liver diseases will be made available .

Intellectual property rights: IP rights of ALL deliverables belong to WHO as per paragraphs 3.1.2 and/or 3.2.2 of the Terms and Conditions

Name(s) of funding sources: The funding will come from various funding sources of Govt of India, Govt of Delhi and Institutional funds.

Activity timeframe: 2023-2027

This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.